Gefen Biomed Investments Ltd engages in the location, screening, and investment in early-stage medical devices and biotechnology companies. The company holds two incubators, ATI and Meytav. It develops technologies for sensing, monitoring, and prevention of mineral scaling on the surface of membranes and pipes in the water treatment industry; KNEE-T-NOLTM, an artificial implant for anterior cruciate ligament reconstruction surgery; and a proprietary nanoparticle-based delivery system for RNAi (gagomers). The company also offers an MRI system for detecting surgical margins in breast cancer surgery; solutions for physiological monitoring and real-time prevention of aspiration pneumonia in enterally-fed patients; and NRD135S, a small molecule to treat chronic pain. In addition, it develops OmniCuff platform, a device for the transosseous rotator cuff repair; pulse oximeter for continuous pulse rate and blood oxygen saturation monitoring; a product line of breast implants for augmentation and reconstruction; and the SpineShield, TendonShield, and NerveShield to address the orthopedic anti-adhesion market. Further, the company develops peripheral stents; Optimized Static Collector, a light concentrator module; Synchronverters, a model of conventional synchronous generators; optical collector for ground and flat roofs PV installations; direct drives for wind and marine turbines; a paradigm of securing critical infrastructures’ Scada systems; a reversible multi polytrophic processes approach for energy storage; an implant technology for aesthetic facial wrinkle treatment; and OrbiShape system for breast plastic surgery. Additionally, it offers iron testing services and laboratory kits for research and treatment centers that specialize in iron overload diseases, as well as for pharmaceutical companies that develop iron chelators. The company is based in Ashkelon, Israel. Gefen Biomed Investments Ltd operates as a subsidiary of BioMedix Ltd.